- Investing.com
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
M&A Strategy | Analysts eye Merck's robust balance sheet and M&A potential, with acquisitions in the $1-15 billion range, as key to filling the post-Keytruda revenue gap |
Pipeline Potential | Learn about Merck's promising pipeline, including TROP2 ADC and KRAS inhibitors, as the company seeks to diversify beyond Keytruda and address future growth |
Gardasil Hurdles | Delve into Merck's strategic pause of Gardasil sales in China, impacting 2025 forecasts and raising concerns about inventory management and market dynamics |
Keytruda's Dominance | Explore Merck's reliance on cancer drug Keytruda, its impressive growth, and the looming patent cliff in 2028 that poses significant revenue challenges |

Metrics to compare | MRK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRKPeersSector | |
|---|---|---|---|---|
P/E Ratio | 16.0x | 19.8x | −0.5x | |
PEG Ratio | 2.00 | 0.36 | 0.00 | |
Price / Book | 5.5x | 3.1x | 2.6x | |
Price / LTM Sales | 4.5x | 4.1x | 3.2x | |
Upside (Analyst Target) | 14.2% | 0.0% | 47.6% | |
Fair Value Upside | Unlock | 41.5% | 6.1% | Unlock |